The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Plinabulin blooms at last for Beyondspring
But the vascular disrupting agent’s unexpected success in a cancer indication might not be as resounding as it seems.
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
